Akums Drugs and Pharmaceuticals Limited is a CDMO offering a wide range of pharmaceutical products and services, including the sale of branded formulations and manufacturing of APIs.

In H1 FY26, Akums' revenue remained flat, but its CDMO business demonstrated a 7% volume growth, despite industry volumes being muted. Margins dipped as API prices fell.

Akums entered a joint venture with the Zambian government to establish a pharmaceutical manufacturing plant, enhancing its international footprint with a $45 million investment over the next few years.

The company's European strategy is progressing with its first commercial supply of formulations to Switzerland, with more products in the pipeline geared for the European market.

Despite challenges, Akums remains in a robust financial position with a net cash surplus of over INR 1,600 crore, supporting organic and inorganic growth initiatives.